Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Ultragenyx stock gains on FDA priority review acceptance By Investing.com
Ultragenyx Pharmaceutical Inc. shares rose after the FDA accepted its Biologics License Application for DTX401, a gene therapy for Glycogen Storage Disease Type Ia, granting it Priority Review. The FDA set an action date of August 23, 2026, for the potential approval of DTX401, which would be the first treatment to address the underlying cause of GSDIa. Clinical data showed patients treated with DTX401 experienced reductions in cornstarch intake, improved euglycemia, and enhanced quality of life.